Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?
Would your recommendation change in a patient having pain from disease and you wanted a quick response?
Answer from: Medical Oncologist at Academic Institution
This is a great question. MSI-H status in PDAC is rare, about 1-2% of all PDAC (Luchini et al., PMID 32350089). Marabelle and colleagues published one of the initial studies using pembrolizumab in MSI-H solid tumors showing a response rate of 18.2% among PDAC (22 patients) with a median duration of ...
Sign in or Register to read more